Navigation Links
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
Date:2/13/2008

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it completed enrollment of patients in the maximum tolerated dose (MTD) cohort expansion segment of its Phase 1/2a trial of RAV12, an anti-cancer monoclonal antibody. The trial enrolled patients with cancers that express the RAAG12 antigen, particularly those of gastrointestinal origin. All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original treatment period. A total of four patients received extended therapy in both the original cohort and the expanded cohort of this trial.

"We continue to be pleased with our advances with RAV12 and the indications of its potential therapeutic value." said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

An analysis of data from this trial is expected in the second or third quarter of this year. The analysis will produce an evaluation of safety, definitive pharmacokinetics, evaluation of immunogenicity, and estimates of efficacy in a refractory patient population.

The appropriate dose and schedule of RAV12 previously was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved side effect profile for the antibody. The recently concluded MTD Cohort Expansion segment involved 20 additional patients. '/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gsqwpp/proteomics ) ... report "Proteomics - Technologies, Markets and Companies" ... describes and evaluates the proteomic technologies that will ... diagnostics and practice of medicine in the post-genomic ... century. Most commonly used technologies are 2D gel ...
(Date:5/28/2015)... -- It takes one act of kindness, one vision and ... hunger and poverty. AbelsonTaylor marks the act on World ... donation to Heifer International will be directed to the ... Tanzania . The donation will reach 1,428 ... lives forever. Nearly 800 million people globally ...
(Date:5/28/2015)... DIEGO , May 28, 2015  Service ... programs, today announced that Fresenius Kabi, a global ... technologies for infusion, transfusion and clinical nutrition, has ... & Performance (SCP) Standards for the seventh ... quantify service effectiveness based upon a stringent set ...
Breaking Medicine Technology:Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 2Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 3AbelsonTaylor Honors World Hunger Day 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3
... 2, 2011 The U.S. Food and Drug Administration ... replace an aortic heart valve damaged by senile aortic ... http://photos.prnewswire.com/prnh/20090824/FDALOGO) Senile aortic valve stenosis is a ... aortic valve that cause the valve to narrow. As ...
... Nov. 2, 2011 Caliper Life Sciences, Inc. (NASDAQ: ... and services for drug discovery and life sciences research, ... (CDAS) unit has launched a new services offering based ... effects of drug candidates on functional activity of proteins ...
Cached Medicine Technology:FDA Approves First Artificial Aortic Heart Valve Placed Without Open-Heart Surgery 2FDA Approves First Artificial Aortic Heart Valve Placed Without Open-Heart Surgery 3Caliper Launches New Platform for Drug Safety Prediction and Oncology Research 2Caliper Launches New Platform for Drug Safety Prediction and Oncology Research 3
(Date:5/29/2015)... Thursday, May 21st was the inaugural Red Nose Day in ... came together to raise money for kids living in poverty. ... to raising money for children and young people living in ... people at Hands-On Seminars decided to host their own event ... fun and laughter to their visitors, while raising awareness of ...
(Date:5/29/2015)... Belviq for weight loss , also ... medication. In 2012, the FDA approved Belviq specifically ... BMI >30. It is also approved for individuals ... weight-related health condition such as high blood pressure, diabetes, ... for weight loss focuses on the brain’s appetite center. ...
(Date:5/28/2015)... 28, 2015 External Counterpulsation (EECP/ECP) has ... over the United States. There are a growing number ... can experience symptoms of angina and these patients are ... and/or bypass surgery. , “No option” patients are a ... artery disease that is considered unacceptable for heart stent ...
(Date:5/28/2015)... May 28, 2015 AMVETS National Executive ... the Commission on Care established by Congress to examine ... veterans. , Appointed to the commission by Mitch McConnell, ... be one of only 15 voting members on the ... and Accountability Act of 2014. The goal of the ...
(Date:5/28/2015)... Dallas, Texas (PRWEB) May 28, 2015 Park ... 2” Group Dog Training class starting Saturday, June ... in the courtyard of 5831 McCommas Blvd in Dallas, with ... The classes will run for five weeks, with no class ... for the class is $135. , In this Intermediate-to-Advanced level ...
Breaking Medicine News(10 mins):Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3
... , TUCSON, Ariz. , ... PRSC ) today announced that Fletcher McCusker , Chairman and ... Company,s operations at the Jefferies 2010 Global Healthcare Services Conference on ... York .   , Providence,s presentation is scheduled for ...
... cheaper and more effective than existing products , WEDNESDAY, ... developed a new formula for a disinfectant that,s effective ... that cause mad cow disease. , The fast-acting disinfectant, ... it could, for instance, be used to rid surgical ...
... N.J. , Jan. 20 Which medical news stories are physicians reading to stay informed about key developments? MedPage ... Every Monday and will be available by visiting MedPageToday.com/Weekly-Top-Ten . , McNeil Expa n ... D r ug R ... z e n in ...
... ... the US marketplace in 2010. , ... Tucson, AZ (PRWEB) January 20, 2010 -- Sunquest, ... business solutions, is introducing its Integrated Clinical Environment™ (Sunquest ICE™) physician portal to ...
... ... solution. State Governments will save billions in medicaid costs, and prevent bankruptcies due to medical ... ... health care reform could bankrupt Medicaid. John Gwynne Prosser II observes California and ...
... Researchers at the University of Minnesota and Minneapolis VA ... brains of those exhibiting post-traumatic stress disorder (PTSD). ... in the study, which for the first time objectively ... magnetic fields in the brain. It,s something conventional brain ...
Cached Medicine News:Health News:Providence Service Corporation to Present at the Jefferies 2010 Global Healthcare Services Conference on Monday, January 25th 2Health News:Providence Service Corporation to Present at the Jefferies 2010 Global Healthcare Services Conference on Monday, January 25th 3Health News:MedPage Today(R) 'What Your Physicians Are Reading' 2Health News:MedPage Today(R) 'What Your Physicians Are Reading' 3Health News:Sunquest Introduces the Integrated Clinical Environment Physician Portal to US Marketplace 2Health News:Author John Gwynne Prosser II Offers "The Solution for Brain Injuries and Bankruptcies" With Free Educational Video Hosted by Google 2Health News:Researchers discover method to objectively identify PTSD 2
Flat serrated handle with polished finish. Spread between curved tips: 2.0 mm. Overall length: 5 inches. Most popular size or model....
Flat serrated handle with polished finish. Spread between curved tips: 1.5 mm. Overall length: 5 inches. Most popular size or model....
Round, knurled handle with polished finish and straight shaft. 1 mm ring curette 1.5 mm high, 33 mm shaft. Overall length: 5.1 inches....
3.5 mm cup. Straight 31 mm shaft with flat handle and polished finish. Overall length: 4.9 inches....
Medicine Products: